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Abstract
MicroRNAs (miRNAs) are short non-coding RNA molecules playing regulatory roles by repressing
translation or cleaving RNA transcripts. Although the number of verified human miRNA is still
expanding, only few have been functionally described. However, emerging evidences suggest the
potential involvement of altered regulation of miRNA in pathogenesis of cancers and these genes
are thought to function as both tumours suppressor and oncogenes.
In our study, we examined by Real-Time PCR the expression of 156 mature miRNA in colorectal
cancer. The analysis by several bioinformatics algorithms of colorectal tumours and adjacent non-
neoplastic tissues from patients and colorectal cancer cell lines allowed identifying a group of 13
miRNA whose expression is significantly altered in this tumor. The most significantly deregulated
miRNA being miR-31, miR-96, miR-133b, miR-135b, miR-145, and miR-183. In addition, the
expression level of miR-31 was correlated with the stage of CRC tumor.
Our results suggest that miRNA expression profile could have relevance to the biological and
clinical behavior of colorectal neoplasia.
Background
MicroRNAs (miRNAs) are 19- to 25-nt non coding RNAs
that are cleaved from 70- to 100-nt hairpin-shaped precur-
sors [1,2]. Initial estimates, relaying mostly on evolution-
ary conservation, suggested there were up to 255 humans
miRNAs. More recent analysis have demonstrated there
are numerous non conserved humans miRNAs and sug-
gest this number may be significantly larger. Although the
precise biological are not yet fully understood, miRNAs
seems to be crucial factors of diverse regulation pathways,
including development, cell differentiation, proliferation
and apoptosis [3-6]. Moreover, miss-regulation of miRNA
expression might contribute to human disease [7-10].
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A more recent link between miRNA function and cancer
pathogenesis is supported by studies examining the
expression of miRNA in clinical samples. Calin et al
reported the first evidence and showed a down-regulation
of miRNA-15 and miRNA-16 in a majority of chronic lym-
phatic leukemia (CLL) [11]. Then, altered miRNA expres-
sion has been reported, in lung cancer [12], breast cancer
[13], glioblastoma [14], hepatocellular carcinoma [15],
papillary thyroid carcinoma [16] and more recently color-
ectal cancer [9]. These results could indicate that miRNA
may be a new class of genes involved in human oncogen-
esis.
Up until very recently, the most common method for
quantifying miRNA was Northern blotting. Over the past
year, a number of different approaches to quantify miR-
NAs have been described, including cDNA arrays [17,18],
a modified Invader assay [19], a bead-based flow cytomet-
ric assay [20] and Real-time PCR [21]. Arrays, invader
assay and bead-base miRNA expression do not amplify
miRNA and thus the sensitivity is often compromised.
The main advantage of real-time PCR is that is more quan-
titative and more sensitive that other high-throughput
assays. However, it could be an important disadvantage if
the number of miRNA increase as expected. In this case,
Real-Time PCR will be less practical than microarrays.
In our study, we analyze by Real-Time PCR the expression
of 156 mature miRNA in colorectal cancer (CRC) cell
lines, tumoral and normal-paired tissues from clinical
samples. CRC is one of the major causes of cancer death
worldwide. At a molecular level, much progress has been
made in the last two decades in the identification and
characterization of the genetic changes involved in the
malignant colorectal transformation process [22]. A
number of molecular studies have shown that colon car-
cinogenesis results from an accumulation of epigenetic
and genetic alterations, including activating mutations of
the K-ras proto-oncogene and inactivating mutations of
APC and TP53 tumor suppressor genes or of DNA repair
genes. However, this stepwise model of colorectal tumor-
igenesis has been mainly validated conceptually, and
there is mounting evidence that alternative genetic events
may occur during colorectal carcinogenesis, sometimes
preferentially, sometimes randomly, and sometimes with
an overlap. miRNA expression regulation could help to
identify mRNA targets associated with different colorectal
carcinogenesis pathways and their role as potential thera-
peutic targets.
In the present study, we examined by Real-time PCR the
expression of 156 mature miRNA in a panel of 16 CRC
cell lines and 12 matched-pair of tumoral and non-
tumoral tissues from patients. We identified a subset of 13
miRNAs differentially expressed in CRC cell lines and
clinical samples.
Results and discussion
miRNA expression in CRC cell lines
In order to investigate miRNA differential expression in
human colorectal cancer, we analyzed by real-time PCR
using TaqMan MicroRNA Assay kit (Applied Biosystems),
the expression of 156 mature miRNAs in total RNA
extracted from 15 CRC cell lines. We compared their
miRNA expression profile with those of CCD-18Co
(human normal colon cell line).
It is generally accepted that gene-expression levels should
be normalized by a carefully selectable stable internal
control gene. However, to validate the presumed stable
expression of a given control gene, prior knowledge of a
reliable measure to normalize this gene in order to
remove any non specific variation is required. To address
this problem we assessed the normalization data using
three different approaches: let-7a (a miRNA that manufac-
turer suggests may be useful as an endogenous microRNA
control according their preliminary data across several
human tissues and cell lines), 18s rRNA (the most stable
housekeeping gene in our CRC samples) and global
median-normalization, similar to microarray analysis.
After normalization, data were transformed as log10 of rel-
ative quantity (RQ) of target miRNA relative to control
sample. As shown Additional file 1, the different normal-
ization approach reveals similar results. Analysis of k-
means clustering (k = 3) identify a group of 22 and 22
miRNA homogeneously up-regulated and down-regu-
lated respectively in all colorectal cancer cell lines and
commonly detected with the three different normaliza-
tion approach used. Figure 1 shows patterns of expression
of these 44 miRNA after normalization with median-glo-
bal normalization. Remarkably this classification only
include those miRNA whose expression are most promi-
nently altered and in addition the expression of this group
of miRNAs is highly reproducible in all cell lines analyzed.
Interestingly, clustering analysis divided CRC cell lines in
two different groups. Analysis of different common
genetic alterations described in colorectal cancer includ-
ing activation of oncogenes (KRAS, BRAF) and inactiva-
tion of tumor supressor genes (TP53) and microsatellite
instability status (MSI) showed that these groups could be
differentiate according the presence of mutation in KRAS
and BRAF genes. One group included DLD1, SW1116,
SW620, SW480, HCT116, Lovo, Colo320, LS174, LS513
and LS411 CRC cell lines. All of them, except for LS411
and Colo320, harbor mutation in KRAS  gene. On the
other hand, the other group includes mainly CRC cell
lines with BRAF mutation (WiDR, SW1417, Caco2 and
RKO). SAM analysis between both groups identified 6Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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miRNA differentially expressed. Colorectal cancer cell
lines with KRAS mutations showed an over-expression of
miR-9, miR-9*, miR-95, miR-148a, miR-190 and miR-
372, in relation to the human normal colon cell line. This
over-expression was lower in whose colorectal cancer cell
lines with mutations in BRAF. The presences of both
mutations were mutually excluding. It is interesting to
note that the predicted miRNA for BRAF regulation (using
miRANDA, TargetScan and PicTar algorithms) included
miR-9. This miRNA was just over-expressed in CRC cell
lines with BRAF wild-type. Moreover, miR-372 has been
recently described as potential oncogene that collaborate
with oncogenic RAS in cellular transformation [23].
In human colorectal cancers, KRAS mutation has been
considered an early event in the development of adeno-
mas [24]. This genetic event is more common in large ade-
nomas than small ones, suggesting that it may be required
for the activation of adenoma progression. Recently, the
activation of BRAF has been reported to occur by somatic
mutation in many human cancers, particularly in human
malignant melanoma (over 60%) [25], human colorectal
cancers (5–15%) [26] and a small fraction of other can-
cers [27,28]. The majority of the BRAF mutations each
represent a single nucleotide change of T-A at nucleotide
1796, resulting in the change of valine to glutamic acid at
codon 599 within the activation segment of BRAF.
Hierarchical clustering of miRNA in CRC cell lines Figure 1
Hierarchical clustering of miRNA in CRC cell lines. 15 CRC cell lines were clustered according to the expression profile of 44 
miRNAs differentially expressed and commonly detected with the three different normalization approach used between CRC 
and normal cell line (average linkage and Euclidean distance as similarity measure). Data from each miRNA were median cen-
tered and RQ was determined as described in material and methods. Dendrograms indicate the correlation between groups of 
samples and genes. Samples are in columns and miRNAs in rows. The expression values ranged from + 5 log10 to - 5 log10.Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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Although BRAF mutations were found in about 5–15% of
colorectal carcinomas, colorectal carcinomas with BRAF
mutations tended to be in lower clinical tumor stages.
However, it has been suggested that alteration in the BRAF
gene may cause the activation of the RAS/RAF/MEK/ERK
pathway [29], consequently increasing cell proliferation
but suppressing the inhibition of apoptosis. Differential
miRNA expression between CRC samples could help to
identify different mechanisms of CRC carcinogenesis
associate with alterations of the RAS/RAF/MEK/ERK path-
way.
As shown table 1, the fold-change observed in CRC cell
lines in relation to CDC18Co differed between -4.5 to -1.5
log10 for down-regulation and 1.4 and 3.8 log10 for up-reg-
ulation. Some of the genes encoding miRNA that are
modulated in CRC cell lines are located in determined
chromosome segments, suggesting that their tumor-spe-
cific expression could be due to DNA abnormalities. In
this context, we observed a preferential down-regulation
in region 14q32.31 including miRNA miR-127, miR-370,
miR-299, miR-154, miR-154*, miR-323, miR-134, miR-
368 and miR-337. By using a computer-assisted approach,
Seitz et al. [30] have identified 46 potential miRNA
located in human 14q32 domain, 40 of which are organ-
ized as a large cluster. Although some of these clustered
miRNA genes appear to be encoded by a single-copy DNA
sequence, most of then are arranged in tandem arrays of
closely related sequences.
However, 14q it is not a region usually deleted in CRC
cancers although their loss have been associated with dis-
ease progression and worse prognosis [31]. On the oppo-
site, we can hypothesize that differential expression could
be regulated by modulation of its transcription. We think
that this hypothesis may be supported by the observation
that different "isoforms" of some down-regulated and up-
regulated miRNAin CRC cell lines are located in different
chromosomes, and their coordinated expression might
reflect the existence of a common target. The expression of
mir-200a, mir-200b and mir-200c, located in two differ-
ent chromosomes (1 and 12) and with a high sequence-
homology, are up-regulated in all CRC cell lines. The anal-
ysis of their putative targets showed MLH1 and MSH2 as
two candidate genes whose transcription could be down-
regulated by miRNA.
Our findings indicate that miRNA expression patterns are
closely related to characteristics of tumor derived cell
lines. These patterns may either mark specific biologic
characteristics or may mediate specific biologic activities
important for the pathobiology of malignant tumors.
miRNA expression in colorectal tumours and adjacent 
non-tumor tissues
In order to investigate whether miRNAs are differentially
expressed in CRC versus normal colon tissues, we ana-
lyzed miRNA expression in 12 matched-pairs of tumoral
and non-tumoral tissues. After testing three different
approaches to normalize the Ct raw data in CRC cell lines,
median-normalization was selected as method for clinical
samples since normal distribution was not required.
Meanwhile in our study in CRC cell lines no differences
were found in let-7a expression between tumoral and nor-
mal cell line, recent evidences identify let7-family as dif-
ferentially expressed in CRC [9] and lung cancer [5].
Moreover, global median normalization could provide
results more easily comparable with those already pub-
lished with microarray technology.
To identify miRNA with significantly differential expres-
sion among CRC samples, two multivariate permutation
test provided in BRB-ArrayTools were performed: Class
Comparison between Groups of Arrays and SAM (Signifi-
cance Analysis of Microarrays). In both cases we selected
paired t-test options and a FDR (False Discovery Rate) less
to 10%. Fifty-nine miRNAs were significant when Class
Comparison test was applied, 68 miRNA were significant
using SAM test and 53 miRNA are common in both test.
As expected, fold-change observed in clinical samples is
less homogeneously distributed among samples that
already obtained in CRC cell lines. It is not surprising
regarding that patients samples are composed of mixed
populations, whereas cell lines are clearly more uniform.
Interestingly, our results in CRC samples are in agreement
with recent data published in CRC using direct miRNA
cloning and SAGE (miRAGE). In this context, we detected
an over-expression of miR-19a, miR-21, miR-29a, miR-
92, miR-148a, miR-200b, and a down-regulation of miR-
30c, miR-133a and miR-145 (figure 2). Moreover, change
of expression of some of these miRNA has been previously
reported in lung and breast cancer, B-cell lymphomas, and
glioblastoma. miR-19a and miR-20 are including in the
cluster miR-17-92 and it is located at intron 3 of C13orf25.
The transfection of C13orf25  in lung cancer cell line
enhancing cell growth and the introduction of miR-17-92
into hematopoietic stem cells in Eu-myc transgenic mice
accelerates the formation of lymphoid malignancies. Fur-
thermore, miR-21 has been described as an antiapoptotic
factor in human glioblastoma cell lines. In contrast, other
authors report that miR-21 suppression increase growth
in HeLa cells without affecting their apoptosis. The differ-
ent biologic effects of any particular miRNA in different
cells could be dependent of the cell-specific repertoire in
target genes. Some of miRNA differentially expressed in
CRC samples have been associated with clinical parame-
ters in other cancers. In particular, miR-145 is progres-Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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sively down-regulated from normal breast to cancer with
high proliferation index and miR-21 is progressively up-
regulated with high grade tumor stage.
To identify the smallest set of predictive miRNAs differen-
tiating normal versus cancer tissues, we have used support
vector machines (SVMs) techniques. We attempted to use
the class prediction tool (BRB-Array tools) that creates a
multivariate predictor for determining to which of the two
classes a given sample belongs. Several multivariate classi-
fication methods are available, including the Compound
Covariate Predictor, Diagonal Linear Discriminate Analy-
sis, Nearest Neighbor Predictor, Nearest Centroid Predic-
tor, and Support Vector Machine Predictor. The classifier
is composed for 18 miRNA, 10 down-regulated and 8 up-
regulated, all of them significantly different by Class Com-
parison and SAM tests.
When we compared expression of these miRNA in CRC
cell lines, 5 of 18 miRNA were revealed in the k-means
analysis as those of highest fold-changes (in relation to
CDC18Co). However, Class Comparison analysis
between 15 CRC cell lines and the 12 non-tumoral colon
tissues identifies 13 miRNA altered in both systems, CRC
patients samples and CRC cell lines (Table 2). These
results could indicate that miRNA profile in CRC cell lines
can not be used to infer miRNA expression in clinical sam-
ples meanwhile cell lines can be used as model to validate
miRNA expression data from 12 CRC tumor samples Figure 2
miRNA expression data from 12 CRC tumor samples. Each miRNA listed was detected as significantly differentially expressed 
between tumoral and paired-non-tumoral tissues with SAM and Class Comparison tests. Samples are in columns and miRNAs 
in rows. The expression values ranged from + 1.5 log10 to - 1.5 log10.Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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and performed functional assays of data obtained in clin-
ical samples. In this sense, hierarchical clustering of
expression of these 13 miRNAs in CRC patients samples
and CRC cell lines clearly separate samples in two groups:
in one branch, the most different of non-tumoral samples
were included all the CRC cell lines, and in the other
branch tumoral samples of patients (Figure 3).
The expression of 5 of 13 miRNA is already described
altered in CRC, lung and breast cancer, glioblastoma, B-
cell lymphoma and CLL. Among the differentially
expressed miRNAs, miR-31, miR-96, miR-133b, miR-
135b, miR-145 and miR-183 as the most consistently
deregulated in CRC. Two of them, miR-133b and miR-
145 were down-regulated and the remaining four, miR-
31, miR-96, miR-135b and miR-183, were up-regulated,
Table 1: miRNA differentially expressed in CRC cell lines.




hsa-miR-145 -4.13 5q32 TGFRII, APC
hsa-miR-370 -4.05 14q32.31 BAX, AKT1
hsa-miR-299 -3.90 14q32.31 B-CATENIN, CDKN1A
hsa-miR-199a -3.80 1q24.3
hsa-miR-154* -3.71 14q32.31 MLH1
hsa-miR-199-s -3.64 19p13.2





hsa-miR-137 -3.05 1p21.3 TGFRII
hsa-miR-368 -3.03 14q32.31
hsa-miR-130a - 3.02 11q12.1 TGFRII
hsa-miR-214 -2.36 1q24.3 TP53, B-CATENIN, TGFRII, BAX, CDKN2B, 
EGFR
hsa-miR-337 - 2.25 14q32.31 CDKN2A
hsa-miR-125b -2.20 11q24.1 VEGF, IGFRI, VEGFR
hsa-miR-199b -2.19 9q34.11
hsa-miR-133a -2.11 18q11.2 BAX, K-RAS





hsa-miR-9* 1.68 5q14.3 TCF4, MSH2
hsa-let-7g 1.73 3p21.2 TGFRII
hsa-miR-372 1.76 19q13.42 TGFRII, SMAD2, MLH1, AKT1
hsa-miR-182* 1.77
hsa-miR-219 1.93 6p21.32 TGFRII
hsa-miR-205 2.21 1q32.2 K-RAS, SMAD4, MSH2, PTEN
hsa-miR-194 2.23 1q41
hsa-miR-142-3p 2.29 APC
hsa-miR-135a 2.36 3p21.2 MSH2
hsa-miR-215 2.42 1q41 IGFRI
hsa-miR-142-5p 2.51 17q23.2
hsa-miR-135b 2.90 1q32.1 MSH2
hsa-miR-141 3.28 12p13.31 APC, MSH2
hsa-miR-182 3.41 7q32.2 IGFRI
hsa-miR-200b 3.44 1p36.33 MLH1
hsa-miR-200c 3.64 12p13.31 MLH1, SMAD2
hsa-miR-96 3.64 7q32.2 K-RAS
hsa-miR-200a 3.73 1p36.33 MSH2
hsa-miR-203 3.77 14q32.33Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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suggesting that they may potentially act as tumor suppres-
sor genes or oncogenes, respectively.
miR-145 was identified as a specific miRNA down-regu-
lated in colorectal neoplasia and analysis of their pre-
miRNA indicate that this reduction is due to posttran-
scriptional process [32]. Recently, Cummins et al
obtained similar results in CRC [9] and down-regulation
of miR-145 have also reported in lung [8] and breast can-
cer [13]. In our study, expression of miR-145 was not
detected in any of 15 CRC cell lines tested and down-reg-
ulation was detected in all tumor samples. Other impor-
tant down-regulated miRNA in our study was miR-133b.
In our knowledge, this miRNA has not previously identi-
fied deregulated in cancer. For both down-regulated miR-
NAs (miR-145 and miR-133b), it may be expected that
potential targets could include oncogenes or genes encod-
ing proteins with potential oncogenic functions. Indeed,
among putative targets for miR-145 with potential onco-
genic functions, Iorio et al [13] described MYCN, FOS,
YES, and FLI, cell cycle promoters such as cyclins D2 and
L1; and MAPK transduction proteins such as MAP3K3 and
MAPK4K4. Among putative targets of miR-133b, the most
notable oncogenic target is KRAS. Interestingly, the proto-
oncogen YES1 and the transduction protein MAP3K3 were
potential targets of both miR-145 and miR-133b.
For the up-regulated miRNAs, miR-135b, miR-31, miR-96
and miR-183, it may be expected that gene targets belong
to the class of tumor suppressor genes. miR-96, miR-182
and miR-183 are located in the same chromosomal
region, 7q32.2. miR-182 was not detected as preferen-
tially over-expressed with the most restricted analysis, but
their up-regulation was clearly observed in CRC cell lines
analysis (table 1). CHES1  protein was identified as a
potential target of both miR-96 and miR-182. CHES 1 is a
member of the forkhead family of transcription factors
that repress genes involved in apoptosis. Other members
of this family, including FOXF2,  FOXK2,  FOXO1A,
FOXO3A and FOXQ1, were also found as putative targets
of miR-182, miR-183 and miR-96.
Finally, our analysis of a small number of CRC samples
compared miRNA expression in tumors according to
pathological stage (stage II versus stage IV). The up-regu-
lation of miR-31 was significantly higher in stage IV than
Hierachical clustering of CRC cell lines and tumor samples by using expression of 13 miRNAs that have found differentially  expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues Figure 3
Hierachical clustering of CRC cell lines and tumor samples by using expression of 13 miRNAs that have found differentially 
expressed between neoplastic conditions (CRC cell lines and tumor samples) and non-tumoral colon tissues. Samples are in 
columns and miRNAs in rows.Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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in CRC samples stage II (p = 0.028) (Figure 4). The expres-
sion levels of miR-31 were higher in the tumor samples
and CRC cell lines in comparison to the non-tumoral
samples and was related to pathological stage, suggesting
that this miRNA could contribute to both, the tumorogen-
esis and the acquisition of a more aggressive phenotype in
CRC. Other members of the forkhead family transcription
factors, such as FOXC2  and FOXP3, were identified as
putative targets of miR-31. Future studies will determine
the correlation between of these miRNAs and their host
genes in CRC.
In summary, our results by Real-time PCR identify altera-
tions of miRNA expression in CRC that may deregulate
cancer-related genes and would provide potential mecha-
nisms that underly in the carcinogenesis and further
acquisition of a more aggressive phenotype in colon can-
cer.
Materials and methods
Cell lines and tissues
The following 16 cancer cell lines were used: CDC18Co
(human normal colon), HCT15, RKO, DLD1, Lovo,
LS411, SW1417, Caco2, LS513, SW1116, HCT116,
SW480, Colo320, SW620, WiDR and LS174. Colorectal
cell lines were cultures in a humidified atmosphere of
95% air, 5% CO2 using recommended medium and 10%
FBS. Colorectal tumours and paired-adjacent normal
colorectal tissues were received from our Institutional
Bank of Tumors. Collection and distribution of colorectal
tissues were approved by the appropriate Institution
Review Board.
RNA extraction, reverse transcription and Real-Time PCR 
quantification
Total RNA was extracted from cells with a cell density of
75% confluent using Trizol® total RNA isolation reagent
(Gibco BRL, Life Technologies, Gaitherburg, MD, USA) as
per the manufacturer's protocol. Total RNA was isolated
from the frozen tissues disrupted using an Ultra Turrax
T25 homogenizer and using Trizol. The concentration was
quantified using NanoDrop Specthophotometer (Nano-
Drop Technologies, USA).
cDNA was synthesized from total RNA using gene-specific
primers according to the TaqMan MicroRNA Assay proto-
col (PE Applied Biosystems, Foster City, CA). Reverse tran-
scriptase reactions contained 10 ng of RNA samples, 50
Real-time PCR analysis of miR-31 expression between stage  II and stage IV tumor samples Figure 4
Real-time PCR analysis of miR-31 expression between stage 
II and stage IV tumor samples. Differences was significant 
after Mann Whitney U test (p = 0.028).
Table 2: miRNA differentially expressed in CRC patients samples and CRC cell lines.
Mean fold-change 
(log10RQ) CRC patients 
samples
Mean fold-change 





hsa-miR-133b -1.01 -3.38 6p12.2
hsa-miR-145 -0.84 -4.95 5q32 ↓ CRC, lung, breast cancer.
hsa-miR-129 -0.67 -0.88 7q32.1
hsa-miR-124a -0.64 -1.11 8p23.1 ↓ lung cancer
hsa-miR-30-3p -0.53 -0.63 6q13
hsa-miR-328 -0.52 -0.65 16q22.1
hsa-miR-19a 0.49 0.96 13q31.3 ↑ CRC, lung cancer, B-cell lymphomas, CLL
hsa-miR-20 0.49 1.01 13q31.3 ↑ lung cancer, poorly differentiated HCC
hsa-miR-21 0.78 0.48 17q23.2 ↑ CRC, glioblastoma, lung, breast cancer, papillary 
thyroid carcinoma
hsa-miR-183 0.88 1.74 7q32.2
hsa-miR-96 1.04 1.99 7q32.2
hsa-miR-31 1.09 2.59 9p21.3
hsa-miR-135b 1.60 1.78 1q32.1Molecular Cancer 2006, 5:29 http://www.molecular-cancer.com/content/5/1/29
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nM stem-loop RT primer, 1 × RT buffer, 0.25 mM each of
dNTPs, 3.33 U/μl MultiScribe reverse transcriptase and
0.25 U/μl RNase Inhibitor (all purchased from cDNA
Archive kit of Applied Biosystems). The 7.5 μl reactions
were incubated in an Applied Biosystems 9800 Therma-
Cycler in a 96-well plate for 30 min at 16°C, 30 min at
42°C, 5 min at 85°C and then held at 4°C.
Real-time PCR was performed using an Applied Biosys-
tems 7300 Sequence Detection system. The 10 μl PCR
included 0.67 μl RT product, 1× TaqMan Universal PCR
master mix and 1 μl of primers and probe mix of the Taq-
Man MicroRNA Assay protocol (PE Applied Biosystems).
The reactions were incubated in a 96-well optical plate at
95°C for 10 min, followed by 40 cycles of 95°C for 15s
and 60° for 10 min. The Ct data was determinate using
default threshold settings. The threshold cycle (Ct) is
defined as the fractional cycle number at which the fluo-
rescence passes the fixed threshold.
Normalization and data analysis
Careful normalization is essential for the accurate quanti-
fication of mRNA levels and commonly, normalization of
the target gene with an endogenous standard, mainly
housekeeping genes, is applied. However for miRNA,
there is not data about the expression of miRNA as nor-
malization control.
In our study, we have tried different approach for normal-
ization data. First, miRNA expression data was normal-
ized to let7-a miRNA (according to the manufacturer's
suggestions). Relative quantification of miRNA expres-
sion was calculated with the 2-ΔΔCt method (Applied Bio-
systems User Bulletin N°2 (P/N 4303859)). The data were
presented as log10  of relative quantity (RQ) of target
miRNA, normalized respect to miR-let-7a and relative to a
calibrator sample. As calibrator, we are used for colorectal
cancer cell lines CDC18Co (human normal colon) and
for CRC samples the paired-normal tissues.
The TaqMan Human Endogenous Control Plate (Applied
Biosystems) precoated with lyophilized primers and
probes for 11 differently commonly human control genes
was also used to asses gene expression in two tumours and
two normal colon tissues. PCR was set up according to the
manufacturer's instructions. Among 11 genes analyzed,
the variability in expression of 18s rRNA was shown to be
the lowest (data not shown). Therefore, our second nor-
malization approach showed the data as log10 of relative
quantity (RQ) of target miRNA, normalized to 18s rRNA
and relative to control sample.
Finally, similar to microarray data, raw data Ct was nor-
malized and analyzed using BRB ArrayTools version 3.3.2.
(Richard Simon and Amy Peng Lam, National Cancer
Institute, Bethesda). After global median normalization,
normalized data were presented as log10 of relative quan-
tity (RQ) of target miRNA relative to a control sample.
Class Comparison and Significant analysis of microarrays
(SAM) was performed to identify differentially expressed
miRNAs between tumors and normal samples.
Visualization of results was performed with the different
normalized data using average linkage and Euclidean dis-
tance as a measurement of similarity using GENESIS Soft-
ware (Alexander Sturn, Institute for Genomics and
Bioinformatics, Graz University of Technology).
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